Sponsor:
BioEclipse Therapeutics
Code:
NCT04282044
Conditions
Solid Tumor, Adult
Triple Negative Breast Cancer
Colorectal Cancer
Hepatocellular Carcinoma
Osteosarcoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
CRX100 suspension for infusion
Fludarabine
Cyclophosphamide
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by BioEclipse Therapeutics on 2024-02-08.